HK1 and HK2 antibodies target hexokinase-1 (HK1) and hexokinase-2 (HK2), key isoforms of the hexokinase enzyme family involved in glycolysis. Hexokinases catalyze the first step of glucose metabolism, phosphorylating glucose to glucose-6-phosphate, which is critical for energy production and biosynthetic pathways. HK1 is ubiquitously expressed, particularly in tissues with high energy demands (e.g., brain, muscle), and is tightly bound to mitochondrial outer membranes via interactions with voltage-dependent anion channels (VDAC). This localization optimizes ATP production by coupling glycolysis to mitochondrial oxidative phosphorylation. In contrast, HK2 exhibits a more restricted expression profile, primarily in insulin-sensitive tissues (e.g., adipose, skeletal muscle) and certain cancers. HK2 is frequently overexpressed in tumors, where it supports the Warburg effect—a metabolic shift favoring aerobic glycolysis for rapid energy and biomass production, even under oxygen-rich conditions.
HK1/HK2 antibodies are essential tools for studying metabolic regulation, cancer biology, and therapeutic targeting. HK2-specific antibodies are particularly valuable in cancer research, as HK2 upregulation correlates with tumor progression, metastasis, and drug resistance. These antibodies enable detection of isoform-specific expression patterns in tissues or cell lines, aiding in biomarker discovery and mechanistic studies. Additionally, HK2 inhibition using antibodies or small molecules has shown preclinical promise in disrupting cancer cell metabolism. HK1 antibodies, meanwhile, help explore its roles in normal physiology and neurodegenerative diseases. Both antibodies are crucial for understanding isoform-specific functions and developing targeted therapies for metabolic disorders and cancer.